Clinical trial
Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
NCT00110500 · Sangamo Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00110500 |
|---|---|
| Title | Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy |
| Official title | A Phase I Dose-Escalation Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy |
| Lead sponsor | Sangamo Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy |
| Intervention type | Genetic |
| Interventions | hVEGF-A |
| Enrollment | 12 |
| Start date | Apr 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | May 10, 2005 |
| Last update posted | Jun 8, 2011 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: